Skip to main content
All Posts By

laurabbook@gmail.com

MEDPAGE TODAY
ResearchTreatments

New Options Challenge Standard Treatments in EGFR-Mutant NSCLC (MARIPOSA and MARIPOSA-2 Trials)

*October 2023* Take home message: In 1L setting, combo of Amivantamab (ami), an EGFR-MET bispecific antibody, and Lazertinib (laz), a CNS-penetrant 3rd-generation EGFR TKI, was evaluated against Osimertinib (osi) in the MARIPOSA study (NCT04487080) for treatment-naïve, EGFR-mutated locally advanced or metastatic NSCLC. After a median follow-up of 22.0 months, ami+laz…
laurabbook@gmail.com
December 24, 2023
lungcancer.net
Coping With Cancer

Sometimes I Feel Frustrated

*October 2023* by Juanita Segura Living with lung cancer is rough. Many look at me and tell me, “Juanita, you look so good,” or “You look so well.” But they don’t know what I’m going through mentally. Yes, we try to stay positive and do positive things, but that’s a chore…
laurabbook@gmail.com
December 24, 2023
Dr Christine Bestvina
ResearchStories

Clinician Spotlight: Dr. Christine Bestvina

*November 2023* This month, we are honored to feature Dr. Christine Bestvina, Assistant Professor at the University of Chicago Medicine Comprehensive Cancer Center, specializing in thoracic oncology. Dr. Bestvina has been connected with the EGFR Resisters since she was a fellow at University of Chicago! She participated in the first…
laurabbook@gmail.com
December 24, 2023
lungevity
FundingResearch

Drs. Susumu Kobayashi and Alexandre Reuben Announced as Recipients of EGFR Resisters/LUNGevity Research Award

*November 2023* WASHINGTON, DC (November 1, 2023) – LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is thrilled to announce the recipients of the EGFR Resisters/LUNGevity Research Award for EGFR-Positive Lung Cancer. EGFR Resisters, a vibrant patient-led community advocating for improved treatment options for patients with EGFR-positive lung cancer,…
laurabbook@gmail.com
December 24, 2023
PR Newswire
ResearchTreatments

Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer

*September 2023* RARITAN, N.J., Sept. 28, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the Phase 3 MARIPOSA study evaluating RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), in combination with lazertinib, an oral third-generation EGFR tyrosine kinase…
laurabbook@gmail.com
December 24, 2023
OBR Oncology
ResearchTreatments

Are New NSCLC Findings Practice Changing, or Is PFS Boost Not Enough?

*October 2023* Findings from the FLAURA2 study, presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, showed that chemotherapy added to osimertinib in the first-line setting significantly increased progression-free survival (PFS) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). However, without data…
laurabbook@gmail.com
December 24, 2023